A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy
IR Woodcock, G Tachas, N Desem, PJ Houweling, EM Yiu, M Kean, J Emmanuel, R Kennedy, K Carroll, K de Valle, J Adams, SR Lamandé, C Coles, C Tiong, D Villano, P Button, J-Y Hogrel, S Catling-Seyffer, MB Delatycki, View ORCID ProfileMM Ryan, ATL1102 in DMD clinical trial group
doi: https://doi.org/10.1101/2022.01.16.22269029
IR Woodcock
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
2The Murdoch Children’s Research Institute, Melbourne, Australia
3Department of Paediatrics, University of Melbourne, Australia
G Tachas
4Antisense Therapeutics Ltd, Melbourne, Australia
N Desem
4Antisense Therapeutics Ltd, Melbourne, Australia
PJ Houweling
2The Murdoch Children’s Research Institute, Melbourne, Australia
3Department of Paediatrics, University of Melbourne, Australia
EM Yiu
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
2The Murdoch Children’s Research Institute, Melbourne, Australia
3Department of Paediatrics, University of Melbourne, Australia
M Kean
5Department of Medical Imaging, The Royal Children’s Hospital, Melbourne, Australia
J Emmanuel
5Department of Medical Imaging, The Royal Children’s Hospital, Melbourne, Australia
R Kennedy
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
2The Murdoch Children’s Research Institute, Melbourne, Australia
6Department of Physiotherapy, University of Melbourne, Australia
K Carroll
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
2The Murdoch Children’s Research Institute, Melbourne, Australia
7Department of Physiotherapy, Monash University, Australia
K de Valle
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
2The Murdoch Children’s Research Institute, Melbourne, Australia
6Department of Physiotherapy, University of Melbourne, Australia
J Adams
2The Murdoch Children’s Research Institute, Melbourne, Australia
SR Lamandé
2The Murdoch Children’s Research Institute, Melbourne, Australia
3Department of Paediatrics, University of Melbourne, Australia
C Coles
2The Murdoch Children’s Research Institute, Melbourne, Australia
C Tiong
2The Murdoch Children’s Research Institute, Melbourne, Australia
D Villano
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
P Button
8McCloud Consulting Group, Sydney, Australia
J-Y Hogrel
9Institut de Myologie, GH Pitié-Salpêtrière, Paris, France
S Catling-Seyffer
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
2The Murdoch Children’s Research Institute, Melbourne, Australia
MB Delatycki
10Victorian Clinical Genetics Service, Melbourne, Australia
11Bruce Lefroy Centre for Genetic Health Research, Murdoch Children’s Research Institute, Melbourne, Australia
MM Ryan
1Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia
2The Murdoch Children’s Research Institute, Melbourne, Australia
3Department of Paediatrics, University of Melbourne, Australia
Article usage
Posted January 19, 2022.
A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy
IR Woodcock, G Tachas, N Desem, PJ Houweling, EM Yiu, M Kean, J Emmanuel, R Kennedy, K Carroll, K de Valle, J Adams, SR Lamandé, C Coles, C Tiong, D Villano, P Button, J-Y Hogrel, S Catling-Seyffer, MB Delatycki, MM Ryan, ATL1102 in DMD clinical trial group
medRxiv 2022.01.16.22269029; doi: https://doi.org/10.1101/2022.01.16.22269029
A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy
IR Woodcock, G Tachas, N Desem, PJ Houweling, EM Yiu, M Kean, J Emmanuel, R Kennedy, K Carroll, K de Valle, J Adams, SR Lamandé, C Coles, C Tiong, D Villano, P Button, J-Y Hogrel, S Catling-Seyffer, MB Delatycki, MM Ryan, ATL1102 in DMD clinical trial group
medRxiv 2022.01.16.22269029; doi: https://doi.org/10.1101/2022.01.16.22269029
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2302)
- Dermatology (205)
- Emergency Medicine (372)
- Epidemiology (11640)
- Forensic Medicine (10)
- Gastroenterology (686)
- Genetic and Genomic Medicine (3640)
- Geriatric Medicine (342)
- Health Economics (625)
- Health Informatics (2337)
- Health Policy (921)
- Hematology (337)
- HIV/AIDS (761)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3395)
- Nursing (193)
- Nutrition (512)
- Oncology (1784)
- Ophthalmology (528)
- Orthopedics (212)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6037)
- Radiology and Imaging (1238)
- Respiratory Medicine (815)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (144)